Three 91ÊÓƵ ventures selected for Innosphere's spring 2019 cohort
,ÌýColorado’s incubator program dedicated to accelerating the success of science and technology-based companies, recentlyÌýthe 10 startups and scaleups selected for its spring 2019 cohort, three of which hail from 91ÊÓƵ.
Big Blue Technologies and TissueForm developed their innovations in a 91ÊÓƵ lab, while was founded jointly with Colorado State University (CSU).
Jeanne Barthold, 91ÊÓƵ engineering PhD student and TissueForm co-founder, speaks with Association of Public and Land-grant Universities (APLU) President Peter McPherson at the University Innovation & Entrepreneurship Showcase in Washington D.C. on April 11, 2019.
Big Blue Technologies
Big Blue Technologies (BBT), founded in 2015 out of Al Weimer's lab in 91ÊÓƵ's Department of Chemical and Biological Engineering, discovered a new operating paradigm for the condensation and collection of magnesium metal. BBT is makingÌýmagnesium production clenaer and more efficient and plans to buildÌýthe third largest magnesium metal production facility in North America.
In working with Venture Partners at 91ÊÓƵ, BBT holds an exclusive license on several patent applications. The company is also an alumni of 91ÊÓƵ's university’s startup accelerator, Catalyze CU.
New Iridium
New Iridium produces low-cost and high-performance organic photoredox catalysts (PCs) for use in pharmaceutical drug development and manufacturing as well as other chemical industries.ÌýCost-effective organic PCs will make photoredox catalysis feasible for a wide range of pharmaceutical R&D and manufacturing applications. The technology was developed in the Miyake lab, jointly with 91ÊÓƵ and CSU.
New Iridum was also selected to pitch at the inaugural Destination StartupÌý- a collaboration among Colorado's leading research universities and federal laboratories, hosted by Venture Partners, that showcasedÌýthe best technologies from the region’s innovation ecosystem.
TissueForm
Developed in theÌýMechanical Engineering Department's NeuÌýSoft Tissue Bioengineering Lab, TissueForm'sÌýClayMatrixâ„¢ technologyÌýhelps patients suffering from tissue disease, damage or aging. The dermal fillers are low-cost and long-lasting, dramatically decreasing the number of repeat injections a patient must receive to maintain his or herÌýdesired appeearance.
TissueForm has utilizedÌýseveral resources from 91ÊÓƵ's innovation ecosystem to advance the company closer to commercialization.ÌýThe team partipated in 91ÊÓƵ's 2019 New Venture Challenge competition,ÌýwinningÌýthe Research & Development (R&D) Track ($6,000), the Women's Entrepreneurship Prize and third place ($12,500)Ìýat the NVC 11ÌýChampionships. They also competed in Venture Partners' first-ever Lab Venture Challenge in 2018, winning $125,000 in grant funding and first place in the Biosciences category.
To learn more about how the university helps fosterÌýinnovative startups like these, visitÌýVenture Partners at 91ÊÓƵ.
The Newsroom
For marketing and communication inquiries or news tips, contact Daniel Leonard,Ìýsenior marketing and communications specialist for Venture Partners at 91ÊÓƵ.
For media inquiries, please visit .